Main image Main image

Cend Therapeutics in the News

November 21, 2017

Saira Ramasastry is a seasoned biotech industry insider with over 20 years of transaction and advisory experience. She serves on the Industry Advisory Board of the Michael J Fox Foundation for Parkinson’s Research, Chief Business Advisor for the European Prevention of Alzheimer’s Dementia (EPAD) consortium, as well as a Special Advisor for the G8 Health Initiatives. Previously she helped found and establish the leading life sciences franchise on Wall Street at Merrill Lynch and was responsible for emerging biotech coverage for over a decade. In addition, Saira has worked in M&A and Restructuring at Wasserstein Perella. Saira has a B.A. in Economics with Honors and Distinction from Stanford University, and advanced degrees in Management Science & Engineering from Stanford University and Management Studies from the University of Cambridge. Saira is a Silicon Valley’s 40 Under 40 (2012), Health Innovator Fellow of the Aspen Institute, and recently named a top global life sciences advisor by Finance Monthly and CorporateLiveWire.

November 8, 2017

Since May 2017, about 20 publications – from almost as many academic groups – have used and independently validated the DrugCendR iRGD tumor penetrating technology. These papers have corroborated our mechanistic understanding on the tumor-specific drug transport (CendR) pathway activated by iRGD peptide, and also further validated its therapeutic efficacy in a variety of tumor models. The complete list is available here.




Number of publications using the DrugCendR iRGD technology

October 23, 2017

DrugCendR Inc. is presenting its well-validated technology for the treatment of solid tumors at the San Diego Innovation Showcase on Thursday, October 26th, 2017. More information on the event website